ProCE Banner Activity

Our Thoughts on Cytokine Release Syndrome With BCMA-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Clinical Thought

Review this expert commentary from clinical pharmacists on cytokine release syndrome and monitoring patients receiving BCMA-targeted therapies for relapsed/refractory multiple myeloma.

Released: June 19, 2023

Share

Provided by

Provided by ProCE

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Partners

Clinical Care Options, LLC 123

ProCE Banner

Hematology/Oncology Pharmacy Association (HOPA)

ProCE Banner